Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463344 | 0.90 | HTR2A (0.32) | KMO | |
| SCHEMBL1746766 | 0.90 | HTR2A (0.32) | KMO | |
| SCHEMBL1746128 | 0.82 | GLS (0.34) | — | |
| SCHEMBL1464500 | 0.74 | GLS (0.38) | KMO | |
| SCHEMBL31717232 | 0.73 | MAOB (0.42) | KMOMAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL1464482 | 0.73 | MAPT (0.33) | HDAC3HDAC2 | |
| SCHEMBL31130030 | 0.72 | BRD4 (0.39) | KMO | |
| SCHEMBL23546502 | 0.72 | KMO (0.41) | KMOMAOAMAOB | |
| SCHEMBL3345161 | 0.71 | HTR2A (0.41) | KMO | |
| Hydrazinecarboxamide SCHEMBL1463300 | 0.70 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871760-B2 | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2480545-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071143-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | P2RX3, P2RX7, P2RX1 | KMO 1456/4885MAOA 1186/4885MAOB 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.